Bernuau J. Acute liver failure: avoidance of deleterious co-factors and early specific medical therapy for the liver are better than late intensive care for the brain (review).
J Hepatol. 2004;41:152-155.
Butterworth RF. Role of circulating neurotoxins in the pathogenesis of hepatic encephalopathy: potential for improvement following their removal by liver assist devices.
Liver Int. 2003;23(suppl 3):5-9. Review.
Hepatic encephalopathy. EBSCO DynaMed website. Available at:
http://www.ebscohost.com/dynamed. Updated February 18, 2014. Accessed March 5, 2014.
Highleyman L. Hepatitis C. HCV Advocate website. Available at:
http://www.hcvadvocate.org/hepatitis/hepC/hepatic%5Fencephalopathy.html. Published December 2002. Accessed February 17, 2014.
Juretschke L. Kernicterus: still a concern.
Neonatal Netw. 2005;24:7-9.
Lizardi-Cervera J, Almeda P, Guevara L, et al. Hepatic encephalopathy: a review.
Ann Hepatol. 2003;2:122-130. Review.
Toftengi F, Larsen F. Management of patients with fulminant hepatic failure and brain edema.
Metab Brain Dis. 2004;19:207-214.
4/2/2010 DynaMed's Systematic Literature Surveillance
http://www.ebscohost.com/dynamed: FDA approves new use of Xifaxan for patients with liver disease. US Food and Drug Administration website. Available at:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm206104.htm. Published March 24, 2010. Accessed February 17, 2014.